(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/201504 A1

(51) International Patent Classification:

| | |
|---|---|
| *A61P 35/00* (2006.01) | *C07D 413/14* (2006.01) |
| *C07D 213/56* (2006.01) | *C07D 493/10* (2006.01) |
| *C07D 213/71* (2006.01) | *C07D 498/18* (2006.01) |
| *C07D 231/12* (2006.01) | *A61K 31/4155* (2006.01) |
| *C07D 401/06* (2006.01) | *A61K 31/415* (2006.01) |
| *C07D 401/12* (2006.01) | *A61K 31/4439* (2006.01) |
| *C07D 403/10* (2006.01) | *A61K 31/422* (2006.01) |
| *C07D 405/10* (2006.01) | *A61K 31/4402* (2006.01) |
| *C07D 405/12* (2006.01) | *A61K 31/454* (2006.01) |
| *C07D 405/14* (2006.01) | *A61K 31/5386* (2006.01) |
| *C07D 413/10* (2006.01) | |

(21) International Application Number:
PCT/CN2025/085642

(22) International Filing Date:
28 March 2025 (28.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2024/084840
29 March 2024 (29.03.2024) CN
PCT/CN2024/117463
06 September 2024 (06.09.2024) CN
PCT/CN2025/072209
14 January 2025 (14.01.2025) CN

(71) Applicant *(for CN only)*: **BEIGENE (SUZHOU) CO., LTD.** [CN/CN]; Building 9, Biological Industrial Park, No. 218, Sangtian Street, Suzhou Industrial Park, Suzhou, China (Jiangsu) Pilot Free Trade Zone, Suzhou, Jiangsu 215002 (CN).

(71) Applicant *(for all designated States except CN)*: **BEIGENE SWITZERLAND GMBH** [CH/CH]; Aeschengraben 27, 4051 Basel (CH).

(72) Inventors: **WANG, Yayi**; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN). **WANG, Qiuwen**; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN). **GUO, Yunhang**; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN). **WANG, Zhiwei**; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN).

(74) Agent: **WU, FENG & ZHANG**; 3Fl, Building 4, Yard 38, Lin Feng Er Lu Road, Greenland Central Square, Haidian District, Beijing 100089 (CN).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: KAT6 INHIBITORS




(I)

(57) Abstract: Disclosed herein are compounds used as inhibitors of KAT6 and pharmaceutical compositions comprising the compounds. Also disclosed are methods for treating a disorder or disease responsive to the inhibition of KAT6 activity in a subject. In an embodiment, the compounds are of formula (I) or a pharmaceutically acceptable salt thereof, or a deuterated analog thereof, or an N-oxide thereof, or a tautomer thereof, wherein values for the variables (e.g., ring B, A', $A^2$, $A^3$, $A^4$, $A^5$, $X^1$, L, $R^{62}$, $R^{63}$, $R^{64}$, $R^7$, and n) are disclosed herein.

WO 2025/201504 A1